Skip to main content
SpringerLink
Log in

Classical multidrug resistance in acute myeloid leukaemia

  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Approximately 15-30% of acute myeloid leukaemia (AML) patients are primarily resistant to chemotherapy, and 60-80% of patients who achieve complete remission will inevitably relapse and succumb to their disease. The multidrug resistant (MDR) phenotype has been suspected as a major mechanism of therapy failure in AML; it is one of the best understood mechanisms of resistance to anticancer drugs. The classical MDR phenotype is characterized by the reduced ability of cells to accumulate drugs as compared to normal cells. The increased drug efflux is due to the activity of a 170 kDa glycoprotein, the P-glycoprotein (Pgp), a unidirectional drug-efflux pump which is encoded by the MDR1 gene. While studies of myeloid leukaemia and myeloma have provided the best evidence for the potential association between Pgp expression and clinical outcome, the lack of standardized methods for MDR detection and, perhaps even more importantly, inconsistencies in the interpretation of MDR expression data account for divergent results in the literature. The clinicians’ strong interest in MDR stems from the availability of agents capable of interfering with MDR, at leastin vitro. If these laboratory results were reproduciblein vivo, reversal of MDR would offer a rare opportunity to incorporate laboratory experience into the clinical management of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Simon, S.M. and Schindler, M. (1994) Ceil biological mechanisms of multidrug resistance in tumors.Proc. Natl. Acad. Sci. USA 91, 3497–504.

    Article  PubMed  CAS  Google Scholar 

  2. Lehnert, M. (1996) Clinical multidrug resistance in Cancer: A multifactorial problem.Eur. J. Cancer 32A, 912–20.

    Article  PubMed  CAS  Google Scholar 

  3. Germann, U.A. (1996) P-glycoprotein-A mediator of multi-drug resistance in tumour cells.Eur. J. Cancer 32A, 927–44.

    Article  PubMed  CAS  Google Scholar 

  4. Loe, D.W., Deelev, R.G. and Cole, S.P.C. (1996) Biology of the multidrug resistance-associated protein, MRP.Eur. J. Cancer 32A, 945–57.

    Article  PubMed  CAS  Google Scholar 

  5. Izquierdo, M.A., Scheffer, G.L., Flens, M.J., Schroeijers, A.B., van der Valk, P. and Scheper, R.J. (1996) Major vault protein LRP-related multidrug resistance.Eur. J. Cancer 32A, 979–84.

    Article  PubMed  CAS  Google Scholar 

  6. Morrow, C.S. and Cowan, K.H. (1990) Glutathione S-transferases and drug resistance.Cancer Cells 2, 15–22.

    PubMed  CAS  Google Scholar 

  7. Nitiss, J.L. and Beck, W.T. (1996) Antitopoisomerase drug action and resistance.Eur. J. Cancer 32A, 958–66.

    Article  PubMed  CAS  Google Scholar 

  8. Kaye, S.B. (1993) P glycoprotein (P-gp) and drug resistance - time for reappraisal?Br. J. Cancer 67, 641–3.

    PubMed  CAS  Google Scholar 

  9. Twentyman, P.R. (1995) Modifiers of multidrug resistance.Br. J. Haematol 90, 735–7.

    Article  PubMed  CAS  Google Scholar 

  10. Lehnert, M. (1996) Clinical multidrug resistance in cancer: A multifactorial problem.Eur. J. Cancer 32A, 912–20.

    Article  PubMed  CAS  Google Scholar 

  11. Weinstein, R.S., Kuszak, J.R., Kluskens, L.F. and Coon, J.S. (1990) P-glycoproteins in pathology: The multidrug resistance gene family in humans.Human Pathol. 21, 34–48.

    Article  CAS  Google Scholar 

  12. Roninson, I.B. (1991)Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York: Plenum Press.

    Google Scholar 

  13. Licht, T., Pastan, I., Gottesman, M. and Herrmann, F. (1994) P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells.Ann. Hematol. 69, 159–71.

    Article  PubMed  CAS  Google Scholar 

  14. Lum, B.L. and Gosland, M.P. (1995) MDR expression in normal tissues.Hematol./Oncol. Clinics of North America 9, 319–36.

    CAS  Google Scholar 

  15. Sikic, B.I. (1993) Modulation of multidrug resistance: At the threshold.J. Clin. Oncol 11, 1629–35.

    PubMed  CAS  Google Scholar 

  16. Twentyman, P.R. (1992) MDR1 (P-glycoprotein) gene expression - implications for resistance modifier trials.J. Natl Cancer Inst 84, 1458–60.

    Article  PubMed  CAS  Google Scholar 

  17. Biedler, J.L. (1994) Drug resistance: Genotypeversus pheno-type - Thirty-second G.H.A. Clowes Memorial Award Lecture.Cancer Res. 54, 666–78.

    PubMed  CAS  Google Scholar 

  18. Chaudhary, P.M., Mechetner, E.B. and Roninson, I.B. (1992) Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes.Blood 80, 2735–9.

    PubMed  CAS  Google Scholar 

  19. Klimecki, W.T., Futscher, B.W., Grogan, T.M. and Dalton, W.S. (1994) P-glycoprotein expression and function in circulating blood cells from normal volunteers.Blood 83, 2451–58.

    PubMed  CAS  Google Scholar 

  20. Pilarski, L.M., Paine, D., McElhaney, J.E., Cass, C.E. and Belch, A.R.(1995) Multidrug transporter P-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes.Am. J. Hematol. 49, 323–35.

    Article  PubMed  CAS  Google Scholar 

  21. Drach, D., Zhao, S., Drach, J., Mahadevia, R., Gattringer, C, Huber, H. and Andreeff, M. (1992) Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype.Blood 80, 2729–34.

    PubMed  CAS  Google Scholar 

  22. Gupta, S., Kim, C.H., Tsuruo, T. and Gollapudi, S. (1992) Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: A role in cytotoxic effector function.J. Clin. Immunol 12, 451–8.

    Article  PubMed  CAS  Google Scholar 

  23. Drach, J., Gsur, A., Hamilton, G., Zhao, S., Angerler, J., Fiegl, M., Zojer, N., Raderer, M., Haberl, I., Andreeff, M. and Huber, H. (1996) Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-γ in normal human T lymphocytes.Blood 88, 1747–54.

    PubMed  CAS  Google Scholar 

  24. Solomon, M., Meenan, B., Heavey, C., and Paietta, E. (1995) Differential modulation of P-glycoprotein, the multidrug resistance mediator, by cremophor in normal versus leukemic hematopoietic cells.Blood 86, 4385–6.

    PubMed  CAS  Google Scholar 

  25. Sato, H., Preisler, H., Day, R., Raza, A., Larson, R., Browman, G., Goldberg, J., Vogler, R., Grunwald, H., Gottlieb, A., Bennett, J., Gottesman, M. and Pastan, I. (1990) MDR11 transcript levels as an indication of resistant disease in acute myelogenous leukemia.Br. J. Haematol,75, 340–5.

    Article  PubMed  CAS  Google Scholar 

  26. Pirker, R., Wallner, J., Geissler, K., Linkesch, W., Haas, O.A., Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P., Havelec, L., Ludwig, H. and Lechner, K. (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia.J. Natl. Cancer Inst 83, 708–12.

    Article  PubMed  CAS  Google Scholar 

  27. Marie, J.-P., Zittoun, R. and Sikic, B.I. (1991) Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome andin vitro sensitivity.Blood 78, 586–92.

    PubMed  CAS  Google Scholar 

  28. Lyttelton, M.P.A., Hart, S., Ganeshaguru, K., Hoffbrand, A.V. and Mehta, A.B. (1994) Quantitation of multidrug resistant MDR1 transcript in acute myeloid leukemia by non-isotopic quantitative cDNA-polymerase chain reaction.Br. J. Haematol. 86, 540–46.

    Article  PubMed  CAS  Google Scholar 

  29. Paietta, E., Andersen, J., Racevskis, J., Bennett, J., Rowe, J.M., Cassileth, P. and Wiernik, P.H. (1994) Multidrug resistance gene (MDR-1) transcript or CD34 antigen expression levels do not predict for complete remissions inde novo adult acute myeloid leukemia (AML): An Eastern Cooperative Oncology Group study.Blood 84 (Supp1 1), 377a, #1494.

    Google Scholar 

  30. Chaudary, P.M. and Roninson, I.B. (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells.Cell 66, 85–94.

    Article  Google Scholar 

  31. Marie, J.-P., Brophy, N.A., Ehsan, M.N., Aihara, Y., Mohamed, N.A., Cornbleet, J., Chao, N.J. and Sikic, B.I. (1992) Expression of multidrug resistance genemdrl mRNA in a subset of normal bone marrow cells.Br. J. Haematol. 81, 145–52.

    Article  PubMed  CAS  Google Scholar 

  32. Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D. and Fiere, D. (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis.Blood 79, 473–76.

    PubMed  CAS  Google Scholar 

  33. Miwa, H., Kita, K., Nishii, K., Morita, N., Takakura, N., Ohishi, K., Mahmud, N., Kageyama, S., Fukumoto, M. and Shirakawa, S. (1993) Expression of MDR1 gene in acute leukemia cells: Association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia.Blood 82, 3445–51.

    PubMed  CAS  Google Scholar 

  34. Samdani, A., Glinsmann-Gibson, B.J., Grimm, M.A., Vijapurkar, U., Spier, C.S., Grogan, T.M and List, A.F. (1994) Relationship of P-glycoprotein (PGP) to karyotype, age, AML type, surface phenotype and treatment outcome in acute myeloid leukemia (AML).Exp. Hematol 22 (311), 761.

    Google Scholar 

  35. Guerci, A., Merlin, J.L., Missoum, N., Feldmann, L., Marchal, S., Witz, F., Rose, C. and Guerci, O. (1995) Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.Blood 85, 2147–53.

    PubMed  CAS  Google Scholar 

  36. Willman, C.L. (1996) Immuphenotyping and cytogenetics in older adults with acute myeloid leukemia: Significance of expression of the multidrug resistance gene-1 (MDR1).Leukemia 10 (Suppl. 1), S33-S35.

    PubMed  Google Scholar 

  37. List, A.F., Spier, C.M., Cline, A., Doll, D.C., Garewal, H., Morgan, R. and Sandberg. A.A. (1991) Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype.Br. J. Haematol 78, 28–34.

    Article  PubMed  CAS  Google Scholar 

  38. Sonneveld, P., van Dongen, J.M., Hagemeijer, A., van Lom, K., Nooter, K., Schoester, M., Adriaansen, H.J., Tsuruo, T. and de Leeuw, K. (1993) High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype.Leukemia 7, 963–69.

    PubMed  CAS  Google Scholar 

  39. Zhou, D.-C, Marie, J.-P., Suberville, A.-M. and Zittoun, R. (1992) Relevance ofmdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods.Leukemia 6, 879–85.

    PubMed  CAS  Google Scholar 

  40. te Boekhorst, P.A.W., de Leeuw, K., Schoester, M., Wittebol, S., Nooter, K., Hagemeijer, A., Löwenberg, B. and Sonneveld, P. (1993) Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells.Blood 82, 3157–62.

    Google Scholar 

  41. Paietta, E., Andersen, J., Racevskis, J., Ashigbi, M., Cassileth, P. and Wiernik, P.H. (1995) Modulation of multidrug resistance in de novo adult acute myeloid leukemia: Variable efficacy of reverting agentsin vitro.Blood Rev. 9, 47–52.

    Article  PubMed  CAS  Google Scholar 

  42. Lamy, T., Drenou, B., Grulois, I., Fardel, O., Jacquelinet, C., Goasguen, J., Dauriac, C., Amiot, L., Bernard, M., Fauchet, R. and Le Prise, P.-Y. (1995) Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay.Leukemia 9, 1549–55.

    PubMed  CAS  Google Scholar 

  43. Paietta, E., Andersen, J., Gallagher, R., Bennett, J., Yunis, J., Cassileth, P., Rowe, J. and Wiemik, P.H. (1994) The immunophenotype of acute promyelocytic leukemia: An ECOG study.Leukemia 8, 1108–12.

    PubMed  CAS  Google Scholar 

  44. Paietta, E., Andersen, J., Racevskis, J., Gallagher, R., Bennett, J., Yunis, J., Cassileth, P. and Wiernik, P.H. (1994) Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses.Leukemia 8, 968–73.

    PubMed  CAS  Google Scholar 

  45. Drach, D., Zhao, S., Drach, J. and Andreeff, M. (1995) Low incidence of MDR1 expression in acute promyelocytic leukemia.Br. J. Haematol. 90, 369–74.

    Article  PubMed  CAS  Google Scholar 

  46. Paietta, E., Andersen, J., Rovve, J., Cassileth, P. and Wiernik, P.H. (1995) Myeloid blast cell maturation determines response in adult de novo acute myeloid leukemia (AML): A response-driven antigen expression analysis in 382 Eastern Cooperative Oncology Group (ECOG) patients.Am. Soc. Clin. Oncol. 14, 86, #47.

    Google Scholar 

  47. Paietta, E., Andersen, J., Yunis, J., Rowe, J.M., Cassileth, P.A. and Wiernik PH (1995) for the Eastern Cooperative Oncology Group. (1995) Expression of the multidrug-resistance gene product, P-glycoprotein (PGP), in adult acute myeloid leukemia (AML): Association with stem cell factor CD34 and specific cytogenetic abnormalities.Acta Haematol 93, (16/5), 261.

    Google Scholar 

  48. Paietta, E., Neuberg, D., Rowe, J.M., Cassileth, P.A. and Wiernik, P.H. (1997) The prognostic significance of immuneprofiles in adult acute myeloid leukemia (AML) varies with age: A comparative analysis of the Eastern Cooperative Oncology Group (ECOG) database.Proc. Am. Soc. Clin. Oncol. in press.

  49. List, A.F. (1996) Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.Leukemia 10, 937–42.

    PubMed  CAS  Google Scholar 

  50. Hegewisch-Becker, S. and Hossfeld, D.K. (1996) The MDR phenotype in hematologic malignancies: Prognostic relevance and future perspectives.Ann. Hematol. 72, 105–17.

    Article  PubMed  CAS  Google Scholar 

  51. Sonneveld, P. (1996) Reversal of multidrug resistance in acute myeloid leukemia and other hematological malignancies.Eur. J. Cancer 32A, 1062–9.

    Article  PubMed  CAS  Google Scholar 

  52. Haber, D.A. (1992) Multidrug resistance (MDR 1) in leukemia: Is it time to test?Blood 79, 295–8.

    PubMed  CAS  Google Scholar 

  53. Broxterman, H.J., Lankelma, J. and Pinedo, H.M. (1996) How to probe clinical tumor samples for P-glycoprotein and multidrug resistance-associated protein.Eur. J. Cancer 32A, 1024–33.

    Article  PubMed  CAS  Google Scholar 

  54. Beck, W.T., Grogan, T.M., Willman, C.L., Cordon-Cardo, C., Parham, D.M., Kuttesch, J.F., Andreeff, M., Bates, S.E., Berard, C.W., Boyett, J.M., Brophy, N.A., Broxterman, HJ., Chan, H.S.L., Dalton, W.S., Dietel, M., Fojo, A.T., Gascoyne, R.D., Head, D., Houghton, PJ., Srivastava, D.K., Lehnert, M., Leith, C.P., Paietta, E., Pavelic, Z., Rimsza, L., Roninson, I.B., Sikic, B.I., Twentyman, P.R., Warnke, R. and Weinstein, R. (1996) Methods to detect P-glycoprotein-associated multidrug resistance in patients’ tumors: Consensus recommendations.Cancer Res. 56,3010–20.

    PubMed  CAS  Google Scholar 

  55. Paietta, E. (1995) Proposals for the immunological classifica- tion of acute leukemias.Leukemia 9, 2147–8.

    PubMed  CAS  Google Scholar 

  56. Paietta, E., Andersen, J., and Wiernik, P.H. (1996) A new- approach to analyzing the utility of immunophenotyping for predicting clinical outcome in acute leukemia.Leukemia 10, 1–4.

    PubMed  CAS  Google Scholar 

  57. Neyfakh, A.A. (1988) Use of fluorescent dyes as molecular probes for the study of multidrug resistance,Exp. Cell Res. 174, 168–78.

    Article  PubMed  CAS  Google Scholar 

  58. Ludescher, C., Thaler, J., Drach, D., Drach, J., Spitaler, M., Gattringer, C, Huber, H. and Hofmann, J. (1992) Detection of activity of P-glycoprotein in human tumor samples using rhodamine 123.Br. J. Haematol 82, 161–8.

    Article  PubMed  CAS  Google Scholar 

  59. Frey, T., Yue, S. and Haugland, R.P. (1995) Dyes providing increased sensitivity in flow-cytometric dye-efflux assays for multidrug resistance.Cytometry 20, 218–27.

    Article  PubMed  CAS  Google Scholar 

  60. Webb, M., Raphael, C.L., Asbahr, H., Erber, W.N. and Meyer, B.F. (1996) The detection of rhodamine 123 efflux at low levels of drug resistance.Br. J. Haematol. 93, 650–5.

    Article  PubMed  CAS  Google Scholar 

  61. Solary, E., Bidan, J.-M., Calvo, F., Chauffert, B., Caillot, D., Mugneret, F., Gauville, C., Tsuruo, T., Carli, P.-M. and Guy, H. (1991) P-glycoprotein expression andin vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukemia and myeloma.Leukemia 5, 592–7.

    PubMed  CAS  Google Scholar 

  62. Marie, J.-P., Faussat-Suberville, A.-M., Zhou, D. and Zittoun, R. (1993) Daunorubicin uptake by leukemic cells: Correlations with treatment outcome and mdr1 expression.Leukemia 7, 825–31.

    PubMed  CAS  Google Scholar 

  63. Xie, X.-Y., Robb, D., Chow, S. and Hedley, D.W. (1995) Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia.Leukemia 9,1882–7.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Montefiore and Albert Einstein Cancer Center, 111 East 210th Street, Bronx, NY, USA

    Elisabeth Paietta

Authors
  1. Elisabeth Paietta
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paietta, E. Classical multidrug resistance in acute myeloid leukaemia. Med Oncol 14, 53–60 (1997). https://doi.org/10.1007/BF02990947

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02990947

Keywords

Search

Navigation